News about public health and drug policy often struggles to tell the whole story. In Policy & Analysis, our writer Joe digs deep into legislation, official government records and specialist research to uncover the substance behind regulatory developments. From shifting legal markets to wider questions of public health, the focus is on what the evidence reveals, what it doesn’t and why it matters.
-
Latest analysis
Old Blighty and Uncle Sam take on semi-synthetic cannabinoids
Britain and America are both moving against HHC, THCA and other cannabinoids made from surplus CBD, but with very different kinds of law. In this edition, I compare a chemist’s list with a lawyer’s definition, then look at the 3…
More analysis
-

Crop or drug? Europe and America part ways on hemp
EU governments want hemp flowers treated as a farm product, while Washington is about to treat most intoxicating hemp products as marijuana. In this edition, I compare the two approaches and what…
-

Ireland’s new ‘health-led’ drugs strategy. Plus: Kratom, and the Netherlands’ state-licensed supply chain
Ireland has accepted its citizens’ call for a ‘health-led’ response to drug possession, while keeping possession a crime. I look at what that means and where cannabis fits, then at how US…
-

Keep it, share it, but don’t sell it: what Massachusetts’ Question 8 would actually do
Massachusetts votes next month on whether to close its licensed adult-use cannabis market, and the ballot text is stranger than the slogans suggest. Also covered in this edition: two US hemp deadlines,…
-

What Lies Ahead for America’s Hemp Industry?
Congress has rewritten the legal definition of hemp, and the changes take effect in November and December. The aim was to shut down a market in unregulated intoxicants. On the way, the…
Merch
Medical card
